Burning Rock Biotech (BNR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached RMB128.6 million ($18.3M), up 0.8% year-over-year, with in-hospital business growth offsetting central lab declines.

• Net loss narrowed to RMB35.7 million ($5.1M) from RMB175.0 million year-over-year, reflecting significant cost reductions.

• Strategic partnership with MGI Tech and NMPA approval for a co-developed NGS-based CDx for lung cancer marked key business milestones.

Financial highlights

• In-hospital revenue rose 17.0% year-over-year to RMB63.8 million, while central lab revenue fell 25.2% to RMB40.0 million.

• Pharma R&D services revenue increased 27.1% year-over-year to RMB24.9 million.

• Gross profit improved 6.9% year-over-year to RMB91.8 million, with gross margin rising to 71.4% from 67.4%.

• Non-GAAP gross margin reached 76.0% in Q3 2024, up from 74.5% a year earlier.

• Operating expenses dropped 50.7% year-over-year to RMB130.4 million, driven by lower share-based compensation and headcount reductions.

Outlook and guidance

• Management highlighted ongoing transition to in-hospital testing and continued focus on operational efficiency.

• Forward-looking statements caution about risks and uncertainties due to market and operating conditions.